Vaso (VASO) Risk Assessment

View and export this data going back to 2006. Start your Free Trial

What is Vaso Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Vaso is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Vaso's Risk Assessment

For the Health Information Services subindustry, Vaso's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaso's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Vaso's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Vaso's Risk Assessment falls into.

Vaso (OTCPK:VASO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Vaso Risk Assessment Related Terms

Thank you for viewing the detailed overview of Vaso's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaso (VASO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vaso Corporation (OTCPK:VASO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

137 Commercial Street, Unit 200, Plainview, NY, USA, 11803

Website

https://www.vasocorporation.com

Vaso Corporation is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.

Executives

Leon Dembo	director	137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Janey Moen	director	137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803
Jun Ma	director	C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Edgar Rios	director	1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102
Michael Beecher	officer: Chief Financial Officer	C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716
Joshua Markowitz	director	3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648
Jonathan P Newton	officer: Vice Pres Finance & Controller	152 RICHMOND AVENUE, AMITYVILLE NY 11701
Peter C Castle	director	C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634
David H Lieberman	director	3061 INDUSTRY DR, LANCASTER PA 17603
Behnam Movaseghi	director	C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101
Nelson Randall Hill	officer: Senior Vice President	3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159
William Edward Dempsey	director	52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4
David Tarachand Singh	officer: Chief Financial Officer	C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590
Joseph Giacalone	director
Derek Enlander	director	88C UNION AVENUE, CENTER MORICHES NY 11934